Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
Daré Bioscience Announces Positive Safety & Acceptability Data From Phase 1 Clinical Trial That Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy
Daré Bioscience, Inc. recently announced that Climacteric, the official journal of the International Menopause Society, published safety and acceptability results...SPECIAL FEATURE - Excipients: Their Future Could Lie in Generics
Contributor Cindy H. Dubin highlights the innovative work being done by several leading companies and exemplifies the importance of excipients to the future of drug development.
BIOAVAILABILITY ENHANCEMENT - Solving Low Solubility Challenges to Optimize Drug Delivery Platforms
David K. Lyon, PhD, discusses how low aqueous solubility NCEs have come to define the innovative pharmaceutical pipelines and how advanced technologies are often required to overcome this issue.
Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib & Stenoparib Combination in Advanced Solid Tumors
Allarity Therapeutics, Inc. recently announced it has dosed the first patient in a Phase 1b clinical study evaluating the combination...Hovione & Ripple Enter Strategic Partnership to Expand Epidel Platform Into Non-Ophthalmic Space
Hovione and Ripple Therapeutics have entered a strategic partnership to expand the use of Ripple’s Epidel® platform beyond ophthalmic applications….
Cingulate & Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate
Cingulate Inc. and Indegene recently announced a joint commercialization agreement to provide commercial support for Cingulate’s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment….
SiSaf & the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer
SiSaf Ltd recently announced its collaboration with the University of Leipzig, Germany, to develop Bio-Courier targeted micro interfering RNAs (miRNA) for the treatment of….
SPECIAL FEATURE - Solubility & Bioavailability: Difficult Beasts to Tame
Contributor Cindy H. Dubin highlights the services many of these outsourced providers offer to enhance solubility and bioavailability and get their clients’ projects to market faster and cost effectively – while maintaining critical quality attributes.
Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea
Daré Bioscience, Inc. recently announced the start of a Phase 1 study evaluating its development program targeted at treating primary...SPECIAL FEATURE - Outsourcing Analytical Testing – Timelines, Regulations & Biologics Drive the Sector
Contributor Cindy H. Dubin interviews leading CDMOs to discuss not just their analytical service offerings, but their strategies for meeting regulatory challenges and ensuring faster project timelines.
